Crossmark

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

Published Online: 2022-01-21

Published Print: 2022-12

Authors

Lai, You-Liang

Wang, Kai-Hung

Hsieh, Hsing-Pang

Yen, Wan-Ching http://orcid.org/0000-0001-8015-9086
Funding

Funding for this research was provided by:

Ministry of Science and Technology, Taiwan (107-2320-B-400-003)

The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by Ministry of Education
License Information

Text and Data Mining valid from 2022-01-21

Version of Record valid from 2022-01-21
More Information

Article History

Received: 26 May 2021

Accepted: 8 January 2022

First Online: 21 January 2022

Declarations

:

: All animal experiments were conducted in accordance with the protocols approved by National Health Research Institutes’ Institutional Animal Care and Use Committee (NHRI-IACUC-106125).

: Not applicable.

: DBPR114 was technology transferred to LaunXP Biomedical, Co. LTD, Taichung City, Taiwan, in 2021.

Document is current